Poseida Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
08/03/2024 01:03
* Poseida Therapeutics Inc PSTX.OQ reported a quarterly
adjusted
loss of 27 cents per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of -39 cents. The mean expectation of
five analysts for the quarter was for a loss of 39 cents per
share. Wall Street expected results to range from -50 cents
to -16 cents per share.
* Revenue rose 148.7% to $25.00 million from a year ago;
analysts
expected $6.65 million.
* Poseida Therapeutics Inc's reported EPS for the quarter
was a
loss of 27 cents.
* The company reported a quarterly loss of $25.35 million.
* Poseida Therapeutics Inc shares had risen by 6.8% this
quarter.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 1% in
the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Poseida
Therapeutics Inc is $12.00
This summary was machine generated from LSEG data March 8 at
01:03 a.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2023 -0.39 -0.27 Beat
Sep. 30 2023 -0.29 -0.35 Missed
Jun. 30 2023 -0.53 -0.32 Beat
Mar. 31 2023 -0.45 -0.45 Met